High incidence of germlineBRCAmutation in patients with ER low-positive/PR low-positive/HER-2neunegative tumors

Which threshold for ER positivity? a retrospective study based on 9639 patients

(2014) M. Yi et al.   ANNALS OF ONCOLOGY

A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors

(2014) Jyothi S. Prabhu et al.   Journal of Cancer

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

(2012) Brenda Deyarmin et al.   ANNALS OF SURGICAL ONCOLOGY

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

(2012) Takayuki Iwamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

(2011) D. G. Evans et al.   JOURNAL OF MEDICAL GENETICS

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

(2010) Mahmoud R. Khoshnoud et al.   BREAST CANCER RESEARCH AND TREATMENT

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

(2010) Janice S. Kwon et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY